Literature DB >> 19804501

Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C.

J F L Cobbold1, M M E Crossey, P Colman, R D Goldin, P S Murphy, N Patel, J Fitzpatrick, W Vennart, H C Thomas, I J Cox, S D Taylor-Robinson.   

Abstract

Combinations of noninvasive markers may improve discrimination of chronic liver disease severity. The aims of this study were to compare four validated serum and ultrasound-based markers of hepatic disease severity head-to-head with liver biopsy and to assess optimal combinations with consideration of cost. A total of 67 patients with biopsy-proven chronic hepatitis C underwent all four techniques on the same visit [aspartate aminotransferase (AST) to platelet ratio index (APRI); Enhanced Liver Fibrosis (ELF) panel; transient elastography (TE) and ultrasound microbubble hepatic transit times (HTT)]. Markers were combined according to increasing financial cost and ordinal regression used to determine contributions. APRI, ELF, TE and HTT predicted cirrhosis with diagnostic accuracy of 86%, 91%, 90% and 83% respectively. ELF and TE were the most reliable tests with an intra-class correlation of 0.94 each. Either ELF or TE significantly enhanced the prediction of fibrosis stage when combined with APRI, but when combined together, did not improve the model further. Addition of third or fourth markers did not significantly improve prediction of fibrosis. Combination of APRI with either ELF or TE effectively predicts fibrosis stage, but combinations of three or more tests lead to redundancy of information and increased cost.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804501     DOI: 10.1111/j.1365-2893.2009.01209.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

Review 1.  Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography.

Authors:  Hitoshi Maruyama; Gamal Shiha; Osamu Yokosuka; Ashish Kumar; Barjesh Chander Sharma; Alaa Ibrahim; Vivek Saraswat; Cosmas Rinaldi A Lesmana; Masao Omata
Journal:  Hepatol Int       Date:  2015-12-22       Impact factor: 6.047

2.  Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

Authors:  Mireen Friedrich-Rust; William Rosenberg; Julie Parkes; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  BMC Gastroenterol       Date:  2010-09-09       Impact factor: 3.067

3.  Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.

Authors:  Shelley S Selph; Alexander D Ginsburg; Roger Chou
Journal:  Syst Rev       Date:  2014-09-19

Review 4.  Advances in ultrasound diagnosis in chronic liver diseases.

Authors:  Hitoshi Maruyama; Naoya Kato
Journal:  Clin Mol Hepatol       Date:  2019-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.